Mirati Therapeutics

Mirati Therapeutics, Inc. operates as a clinical-stage oncology company. engages in the development of novel therapeutics. The firm's products target the genetic and immunological promoters of cancer. Its clinical pipeline consists of Adagrasib, MRTX1133, and Sitravatinib. The company was founded on December 13, 1995, and is headquartered in San Diego, CA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Mirati Therapeutics reports successful KRAZATI launch amidst financial challenges

Mirati Therapeutics had a transformative year with the successful launch of KRAZATI for KRAS G12C mutated lung cancer.
Despite a net loss in Q4 2022, the company ended the year with a strong cash position and positive market feedback.
Challenges include financial losses, maximizing target inhibition with PRMT5 inhibitors, and regulatory hurdles for Phase 3 trials.
Opportunities lie in collaborations, combination therapies, Phase 3 trials, and advancing pipeline products for future growth.

Mirati Therapeutics reports strong Q1 performance and advances pipeline

Mirati Therapeutics showcased a strong financial performance in Q1 2023, driven by the successful launch of KRAZATI and progress in clinical studies for MRTX1133. The company's commitment to advancing its pipeline and addressing inquiries from analysts reflects a strategic focus on innovation and stakeholder engagement. Despite facing challenges such as a significant net loss, Mirati remains well-positioned with a robust cash position and promising growth opportunities.

Mirati Therapeutics reports strong Q2 performance and navigates strategic challenges

Mirati Therapeutics showcased strong commercial performance, promising clinical data, and proactive financial management strategies in its Q2 2023 Earnings Call.
While facing challenges in market positioning, trial complexities, and operational management, the company remains well-positioned to capitalize on opportunities in advancing its pipeline and optimizing financial performance.
Analysts' inquiries highlighted key areas of interest and concern, signaling the importance of strategic decision-making, regulatory navigation, and competitive positioning for Mirati's future success.
Overall, Mirati's focus on innovation, patient outcomes, and financial sustainability underscores its commitment to driving therapeutic advancements, addressing unmet medical needs, and delivering long-term value to stakeholders.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Mirati Therapeutics Inc is a Biotechnology company located in 9363 Towne Centre Dr, San Diego, CA, United States.

Mirati (MRTX) delivered earnings and revenue surprises of 6.15% and 75.17%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Mirati (MRTX) Reports Q4 Loss, Misses Revenue Estimates

SAN DIEGO , Feb. 28, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a commercial stage biotechnology company, today announced financial results for the fourth quarter and full year of 2022 along with recent corporate updates. "2022 was a momentous year for Mirati, culminating in the approval and launch of KRAZATI™ as a treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a KRASG12C mutation.

Mirati Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Updates

SAN DIEGO , Feb. 21, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a targeted oncology company, will participate at the 43rd Annual Cowen Health Care Conference on March 6 at 11:10 a.m. P.T. / 2:10 p.m.

Mirati Therapeutics to Participate at the 43rd Annual Cowen Health Care Conference

SAN DIEGO , Feb. 14, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a targeted oncology company, will announce financial results for the fourth quarter and full year of 2022 along with recent corporate updates on February 28, 2023. During a conference call at 4:30 p.m.

Mirati Therapeutics to Report Fourth Quarter and Full Year Financial Results for 2022 and Recent Corporate Updates on February 28, 2023

The shares of Mirati Therapeutics Inc (NASDAQ:MRTX) have been pulling back on the charts this month, after running into the $55 level.

Technical Pressure Could Drag Biotech Lower

Today, we take a deeper look at mid-cap oncology name Mirati Therapeutics for the first time in several years. The company's first FDA approval and some other positive milestones have been overshadowed over the past two months by some disappointing trial data.

Mirati Therapeutics: Suddenly A Battleground Stock

SAN DIEGO, Feb. 1, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a targeted oncology company, will participate in two upcoming healthcare conferences. Wednesday, February 8 at 7:45 a.m.

Mirati Therapeutics to Participate in Two Upcoming Healthcare Conferences

Mirati Therapeutics (MRTX) announces IND clearance for oral KRASG12D selective inhibitor, MRTX1133, by the FDA. It is set to initiate phase I/II study in early 2023.

Mirati (MRTX) KRAS Candidate MRTX1133 to Enter Clinical Stage

IND demonstrates Mirati's leadership in KRAS, representing the Company's third KRAS or KRAS-signaling program to enter clinical development SAN DIEGO , Jan. 19, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), announced today the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application of MRTX1133, a potential first-in-class oral KRASG12D selective inhibitor for clinical evaluation. KRASG12D mutations impact approximately 180,000 patients in the US and Europe, representing approximately a 2.5-fold increase in prevalence compared to KRASG12C mutations.

Mirati Announces IND Clearance by U.S. FDA Enabling Phase 1 Initiation for First-in-Class Oral KRASG12D Selective Inhibitor, MRTX1133

AMC Entertainment

Global Business Travel Group I

Guardant Health Inc

Immunovant Inc

Maxar Technologies

Madrigal Pharmaceuticals

Intellia Therapeutics

Rumble Inc

Prometheus Biosciences

Mid-cap companies are fast-growing, young companies that are not as volatile as small-cap and not as stable as large-cap companies.

These Were the 5 Best and Worst Performing Mid-Cap Stocks in Dec 2022

Philadelphia, Pennsylvania--(Newsfile Corp. - January 6, 2023) - Kaskela Law LLC announces that it is investigating Mirati Therapeutics, Inc. (NASDAQ: MRTX) on behalf of the company's long-term investors.The investigation seeks to determine whether Mirati has issued false and misleading statements and/or failed to disclose material facts to its investors, thereby violating the securities laws and causing harm to the company's shareholders.Mirati shareholders are encouraged to contact Kaskela Law LLC (Adrienne Bell, Esq.

Kaskela Law LLC Announces Investigation of Mirati Therapeutics, Inc. (MRTX) and Encourages Long-Term MRTX Investors to Contact the Firm

SAN DIEGO , Dec. 22, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a commercial-stage targeted oncology company, today announced that the Company will present at the 41st J.P. Morgan Annual Healthcare Conference, on January 9, 2023.

Mirati Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

The FDA bestows a Breakthrough Therapy designation to Mirati's (MRTX) Krazati (adagrasib) for treating patients with advanced, KRAS-mutated colorectal cancer.

Mirati's (MRTX) Krazati Gets Breakthrough Therapy Tag for CRC

Mirati Therapeutics (NASDAQ: MRTX ) stock is rising on Thursday as investors react to a special designation from the FDA. This has the FDA granting Breakthrough Therapy Designation (BTD) to Mirati Therapeutics' adagrasib in combination with cetuximab.

Why Is Mirati Therapeutics (MRTX) Stock Up Today?

ProQR Therapeutics

Two biotech stocks are in the spotlight today, ProQR Therapeutics NV (NASDAQ:PRQR) and Mirati Therapeutics Inc (NASDAQ:MRTX), with the former attracting plenty of options activity.

2 Biotech Stocks Making Headlines

Shares of Mirati Therapeutics Inc. MRTX, +0.10% jumped 6.0% in premarket trading on Thursday after the company said the Food and Drug Administration granted a breakthrough therapy designation to Krazati as a treatment for colorectal cancer. The drug is already approved to treat certain kinds of non-small cell lung cancer.

Mirati Therapeutics gets a Breakthrough designation for its colorectal cancer drug

U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for adagrasib (KRAZATITM) in combination with cetuximab in patients with KRASG12C-mutated advanced colorectal cancer (CRC) whose cancer has progressed following prior treatment with chemotherapy and an anti-VEGF therapy. Journal publication marks second New England Journal of Medicine (NEJM) inclusion in 2022 for adagrasib.

Mirati announces Adagrasib (KRAZATI™) Receives Breakthrough Therapy Designation from FDA for Patients with Advanced, KRAS-Mutated Colorectal Cancer and NEJM Publishes Phase 1b/2 Data from Adagrasib With or Without Cetuximab in Colorectal Cancer

Shares of Mirati Therapeutics Inc. MRTX, -0.81% were up about 3% in premarket trading on Tuesday, the day after the company said it received an accelerated approval from the Food and Drug Administration for a treatment for some people with advanced or metastatic non-small cell lung cancer. The drug, Krazati, can be used in patients who have a KRAS mutation; Agilent Technologies Inc. A, +1.56% and Qiagen QGEN, +1.16% both have FDA-approved companion diagnostics that can test for the mutation.

Mirati's lung cancer drug gets an accelerated approval

The accelerated approval of Mirati Therapeutics' (MRTX) Krazati is based on ORR and DOR data from the phase II registration-enabling cohort of the KRYSTAL-1 study.

Mirati (MRTX) Up on FDA Nod to Adagrasib for KRAS Mutated NSCLC

QIAGEN

GERMANTOWN, Md. & HILDEN, Germany--( BUSINESS WIRE )--QIAGEN (NYSE:QGEN; Frankfurt Prime Standard: QIA) has announced the U.S. Food and Drug Administration (FDA) approval of its therascreen ® KRAS RGQ PCR kit (therascreen KRAS kit) as a companion diagnostic test to Mirati Therapeutic's drug KRAZATI ® (adagrasib) for non-small cell lung cancer (NSCLC).

QIAGEN receives FDA approval for companion diagnostic to Mirati Therapeutics' KRAZATI in non-small cell lung cancer

SAN DIEGO , Dec. 12, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc.  (NASDAQ: MRTX), a targeted oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for  KRAZATI ™ (adagrasib), a targeted treatment option for adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy. Experience the full interactive Multichannel News Release here: https://www.multivu.com/players/English/8999051-mirati-therapeutics-fda-accelerated-approval-of-krazati-adagrasib/ This indication is approved under accelerated approval based on objective response rate (ORR) and duration of response (DOR).

Mirati Therapeutics Announces U.S. FDA Accelerated Approval of KRAZATI™ (adagrasib) as a Targeted Treatment Option for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation

Amgen

Mirati won FDA approval for its rival to Amgen's lung cancer drug on Monday. The approval comes as MRTX stock continues to experience wild swings.

Mirati Wins FDA Approval For Amgen-Rivaling Cancer Drug As Wild Stock Swing Continues

Mirati Therapeutics Inc MRTX shares are trading lower by 4.90% to $41.70 after Citigroup downgraded the stock from Buy to Neutral.

Why Mirati Therapeutics Shares Are Nosediving - Mirati Therapeutics (NASDAQ:MRTX)

Mirati (MRTX) reported earnings 30 days ago. What's next for the stock?

Why Is Mirati (MRTX) Down 19.9% Since Last Earnings Report?

Mirati Therapeutics Inc MRTX shares are trading lower by 12.18% to $43.55 during Thursday's session after multiple analysts downgraded their ratings on the stock and lowered their price targets. Shares are also lower on continued weakness after the company announced late-breaking results evaluating concurrent adagrasib and pembrolizumab in first-line advanced/metastatic non-small cell lung cancer.

News for Mirati Therapeutics Stock (MRTX)